Allogeneic Tumour Lysate
Advanced Renal Cell Carcinoma
Inge Marie SvanePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Advanced Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trebananib National Cancer Institute (NCI) | Phase 2 | BB |
CLOSTRIDIUM BUTYRICUM MIYAIRI 588 City of Hope Medical Center | Phase 3 | BB |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Telaglenastat Calithera Biosciences, Inc | Phase 2 | B |
Dfn-15 Case Comprehensive Cancer Center | Phase 2 | B |
View all 32 →
Same molecule, other indications
Allogeneic Tumour Lysate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →